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Abstract
Background: Tissue inhibitor matrix metalloproteinase 1 (TIMP1) plays a vital role in carcinogenesis, yet its precise
functional roles and regulation remain unclear. In this study, we aim to investigate its biological function and
clinical significance in human colon cancer.
Methods: We analyzed the expression of TIMP1 in both public database (Oncomine and TCGA) and 94 cases of
primary colon cancer and matched normal colon tissue specimens. The underlying mechanisms of altered TIMP1
expression on cell tumorigenesis, proliferation, and metastasis were explored in vitro and in vivo.
Results: TIMP1 was overexpressed in colon tumorous tissues and lymph node metastasis specimens than in normal
tissues. The aberrant expression of TIMP1 was significantly associated with the regional lymph node metastasis
(p = 0.033), distant metastasis (p = 0.039), vascular invasion (p = 0.024) and the American Joint Committee on
Cancer (AJCC) stage (p = 0.026). Cox proportional hazards model showed that TIMP1 was an independent prognostic
indicator of disease-free survival (HR = 2.603, 95 % CI: 1.115–6.077, p = 0.027) and overall survival (HR = 2.907, 95 % CI:
1.254–6.737, p = 0.013) for patients with colon cancer. Consistent with this, our findings highlight that suppression of
TIMP1 expression decreased proliferation, and metastasis but increased apoptosis by inducing TIMP1 specific regulated
FAK-PI3K/AKT and MAPK pathway.
Conclusion: TIMP1 might play an important role in promoting tumorigenesis and metastasis of human colon cancer
and function as a potential prognostic indicator for colon cancer.
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Background
Colon cancer represents one of the most common ma-
lignancies worldwide and a common cause of morbidity
and mortality [1]. Despite increased treatment advances
in the past 20 years, early diagnosis can still improve the
prognosis of this disease [2]. Molecular studies have
revealed a large number of genetic alterations that occur
during colon carcinogenesis, however, precise genetic
changes responsible for the occurrence and progression
of colon cancer is still poorly understood [3, 4].
Therefore, identification of molecular markers remains
crucial for designing novel and efficient treatment
strategy.
Tissue inhibitor matrix metalloproteinase 1 (TIMP1),
located on chromosome Xp11.3-p11.23, belongs to the
Tissue Inhibitor of Metalloproteinases family which in-
cluded four identified members (TIMP1, TIMP2,
TIMP3, and TIMP4). TIMP1 encodes a 931 base-pair
mRNA and a 207 amino acid protein. Studies have
shown that this protein may inhibit the proteolytic activ-
ity of matrix metalloproteinases (MMPs) by forming
noncovalent 1:1 stoichiometric complexes and regulate
the balance of matrix remodeling during degradation of
extracellular matrix [5]. In addition to its inhibitory
effect on most of the known MMPs, which are thought
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to be crucial for the tumor invasion and development of
metastatic disease [6], TIMPs also play an important role
in the regulation of cell proliferation and anti-apoptotic
function [7–9]. Studies in vitro have demonstrated that
overexpression of TIMP1 can lead to a substantially in-
crease of genes involved in proliferation, apoptosis and
signal transduction [5]. In addition, TIMP1 was found to
decrease tumor cell sensitivity to multiple anticancer
drugs by activation of downstream pathways and exhib-
ited anti-apoptotic activity. Specifically, the TIMP1 could
degrade cyclinB1 and activate the NF-kβ signaling path-
way to protect breast cancer cells against chemotherapy-
induced cell death [10]. In particular, it has also been
demonstrated that TIMP1 might bind to the CD63/in-
tegrin β1 complex causing anti-apoptotic effects [11].
Recently, clinical studies have shown that the aberrant
expression of TIMP1 is associated with an unfavorable
prognosis in a series of tumors, such as gastric cancer
[12], papillary thyroid carcinoma [13], cutaneous melan-
oma [14] and breast cancer [8]. The expression level of
TIMP1 often correlates with the TNM stage, disease-
free survival, the rate of tumor recurrence and even the
extent of liver metastasis. Furthermore, TIMP1 is a
secretory protein that could be detected in blood and
body fluid by enzyme linked immunosorbent assay
(ELISA). The expression level of TIMP1 was significantly
increased in the blood of patients with gastric cancer
[12] and familial pancreatic cancer [15], which could
make it as a potential serum marker. However, the pre-
cise function and underlying mechanisms of TIMP1 re-
main to be elucidated in colon cancer.
In the present study, we investigate the expression of
TIMP1 at the mRNA and protein level in human colon
cancer and clarify the correlation between the TIMP1
expression and clinicopathological parameters. We also
sought to determine the role of TIMP1 in colon cancer
cell biological function and the underlying molecular
mechanisms.
Methods
Patient information and clinical specimens
A total of 94 patients who had surgery for colon can-
cer between January 2007 and December 2009 at the
Shanghai General Hospital were selected for this
study. This study was approved by the Institutional
Research Ethics Committee of Shanghai General Hospital.
Patients received neither chemotherapy nor radiotherapy
before surgery. There were 47 male and 47 female with a
median age of 67 years (range, 36–92 years) at the time of
operation. The tumor stage classification was determined
by at least two pathologists who were blinded to the data
according to the American Joint Committee on Cancer
(AJCC). Disease-free survival (DFS) and overall survival
(OS) rates were defined as the interval from initial surgery
to clinically or radiologically proven recurrence/metastasis
and death, respectively. Cancer tissues and metastatic
lymph nodes obtained from patients were immediately
fixed in formalin and embedded in paraffin for immuno-
histochemical (IHC) studies after dehydration. Fresh
samples were dissected manually and were immediately
stored in liquid nitrogen until western blot analysis. Writ-
ten and informed consent was obtained from all patients
before enrollment in the study.
The Oncomine,Cancer Genome Atlas (TCGA) and
Protein-Protein Interaction (PPI) network
Oncomine (www.oncomine.org) was used to acquire
TIMP1 RNA expression in colon carcinoma and normal
mucosae. TCGA RNA-Seq (level 3) and corresponding
clinical data were downloaded from TCGA website
(https://tcga-data.nci.nih.gov/tcga/) following approval of
this project by the consortium. RNA-Seq analysis used
data from 45 stage I, 108 stage II, 80 stage III and 38
stage IV colon cancers and 40 adjacent normal tissues.
To further analyze the function of the significant bio-
markers, the Retrieval of Interacting Genes/Proteins
(STRING database v10.0) resource was utilized for PPI
network analysis and prediction of protein-protein inter-
actions. Proteins were linked based on the following six
criteria: neighborhood, gene fusion, co-occurrence, co-
expression, experimental evidence and existing data-
bases. A p value of less than 0.05 was considered as the
cut-off criterion. TIMP1’s PPI network containing the
top 20 confident proteins were built in Additional file 1:
Figure S1.
Gene Set Enrichment Analysis (GSEA)
GSEA is a method of analyzing and interpreting micro-
array and such data using biological knowledge. The
data firstly generated an ordered list of all genes accord-
ing to their correlation with TIMP1 expression, and then
a predefined gene set receives an enrichment score (ES),
which is a measure of statistical evidence rejecting the
null hypothesis that its members are randomly dis-
tributed in the ordered list. GSEA was performed
using The Cancer Genome Atlas (TCGA) colorectal
cancer (CRC) dataset by GSEA version 2.2 from the
Broad Institute at MIT.
Western blot assays
Total protein was extracted from colon tumors and their
adjacent normal tissues of 4 patients using RIPA lysis buf-
fer with inhibitor phenylmethanesulfonyl fluoride (PMSF)
and then the concentration was measured with BCA pro-
tein assay kit (Beyotime Biotechnology, Jiangsu, China).
Equal amounts of protein (30 μg) were subjected to 10 %
sodium dodecyl sulfate-polyacrylamide gelelectrophoresis
and then transferred onto PVDF membranes. The
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membranes were blocked in 5 % non-fat milk with
0.1 % Tween for 1 h at room temperature followed
by incubating at 4 ∘C overnight with primary rabbit
polyclonal antibody against human protein TIMP1
(1:1000 dilution, Abcam, USA) and β-actin (1:1000
dilution, Abcam, USA). After washing with TBST
buffer, the membrane was incubated with secondary
antibodies conjugated to horseradish peroxidase. The
anti-β-actin antibody was used as loading controls.
The proteins were detected by ECL chemilumines-
cence kit (Pierce Biotechnology, Rockford, IL, USA)
according to the manufacturer’s instructions.
Immunohistochemical analysis
Sections (4-μm thick) were blocked with 3 % H2O2 after
dewaxing and rehydrating in a graded series of ethanol.
Then, pressure cooker mediated antigen retrieval
process was performed in 0.01 M sodium citrate solu-
tion (pH 6.0) and the expression of TIMP1 was tested
using standard immunohistochemical methods [16]. The
corresponding primary antibody was used as follow-
s,TIMP1 (1:100 dilution, Abcam, USA). Immunoreactiv-
ity was evaluated independently by two pathologists who
were blinded to patient information. The evaluation was
based on the staining intensity and the area of staining.
The staining intensity was graded as follows: 0, no stain-
ing; 1, mild staining; 2, moderate staining; and 3, intense
staining. The staining area was scored as follows: 0, no
staining of cells; 1, 1–25 %; 2, 26–50 %; 3, 51–75 %; and
4, 76–100 %. The sum of staining score (intensity and
extension) index was used as the final staining score,
graded as follows: 0–1, negative expression; 2–4, weakly
positive expression; and 5–6, strongly positive expres-
sion. Weakly positive and strongly positive were consid-
ered as positive.
Plasmids construction, transfections and lentiviral
transduction
The control shRNA lentivirus, and TIMP1 shRNA lenti-










For lentivirus transfections, colon cancer cells were
transfected with 5 μg of lenti-TIMP1-virus or lenti-control
virus. Methods used for lentivirus production and infec-
tion were performed as described previously [16].
RNA extraction, reverse transcription PCR and
quantitative real-time PCR (qPCR)
Total RNA was prepared from cell cultures using TRIzol
reagent (TaKaRa, Japan) according to the manufacturer’s
instructions. First strand cDNA was synthesized from
2 μg of total RNA using RevertAid™First Strand cDNA
Synthesis Kit (Fermentas, USA). The quantitative real-
time PCR primers were provided by Sheng Gong Com-









The reaction was performed for 40 cycles of 95 °C for
2 min, and then 95 °C for 10 s, 60 °C for 30 s, and 72 °C
for 30 s, with a final extension at 72 °C for 30 s. Relative
quantities (Δ cycle threshold (Ct) value) were obtained
by normalizing to β-actin. Each reaction was performed
in triplicate.
Cell proliferation and plate colony formation assays
Cells were seeded into 96-well plates (2000 cells per
well), cultured for 24 h, and then measured using 10 μl
Cell Counting Kit-8 (CCK-8; Dojindo Laboratories,
Japan) in 100 μl medium per well for 1 h at 37 °C, and
then absorbance was measured at 450 nm. For plate col-
ony formation assays, 800 cells were seeded in six-well
plates and cultured at 37 °C under a humidified atmos-
phere containing 5 % CO2 for 2 weeks. The cells were
then fixed with methyl alcohol for 30 min and stained
with Giemsa solution for 10 min. Colonies were then
counted and photographed. All experiments were per-
formed in triplicate.
Cell scratch-wound assay
Cells were grown in 6-well plates until confluence. A
wound was generated by scraping with a 10 ul tip. After
12 h, the cells in the wounded monolayer were photo-
graphed and cell migration was assessed by measuring
gap sizes at multiple fields.
Tumor cell invasion assays
Boyden chambers with filter inserts (pore size, 8-μm)
coated with Matrigel in 24-well dishes (BD Biosciences,
USA) was performed to detect tumor cell invasion
assays. Colon cancer cells with different treatment were
then harvested, and 1 × 105 cells were seeded in serum-
free medium into the upper chamber, whereas medium
supplemented with 20 % fetal bovine serum was applied
to the lower chamber as a chemoattractant to induce
Song et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:148 Page 3 of 12
invasion. The migrated cells on the lower side of the
filters were defined as invasive cells and counted at ×
200 magnification in 10 different fields of each filter.
Confocal laser scanning microscopy
Cells were seeded into 35 mm glass bottom dishes with
10 mm microwell overnight. After permeabilized with
0.3 % Triton X-100 diluted in PBS for 15 min and then
blocked with 5 % skimmed milk for 1 h, cells were incu-
bated with primary antibody at 4 °C overnight. After
washed with PBS three times for 5 min each time, cells
were subjected to fluorescent secondary antibody at
room temperature for 1 h. Before confocal microscopy
analysis, cells were counterstained with DAPI.
Flow cytometric analysis
The apoptotic status was analyzed by using an Annexin
V-APC/PI Apoptosis Kit (eBioscience, CA, USA) in ac-
cordance with the manufacturer’s instructions. Briefly,
cells (1 × 106cells/mL) were collected by EDTA treat-
ment and incubated with a mixture of annexin V-FITC
and PI for 15 min at room temperature. The number of
apoptotic cells was analyzed by flow cytometry (BD
Accuri C6, USA).
Animal experiments
Male BALB/c athymic nude mice (4–6 weeks old) pur-
chased from the Institute of Zoology, Chinese Academy
of Sciences of Shanghai. All mice were injected subcuta-
neously into the right side of back with 1.0 × 107 cells to
establish the CRC xenograft model. One week after first
injection, the two groups were sacrificed. Tumor diame-
ters were measured at regular intervals with digital cali-
pers, and tumor volume was calculated by the formula:
tumor volume (mm3) = shorter diameter2 × longer diam-
eter/2. To further investigate the metastasis effect of
TIMP1 in vivo, we used a CRC metastasis model in male
BALB/c-nu/nu mice. A total of 1 × 106 cells were in-
fected with lenti-LUC virus and injected into the tail
veins of nude mice. In weekly intervals, anesthetized
mice were injected i.p. with D-luciferin (150 mg/kg) and
imaged 10 min after injection using the IVIS Illumina
System (Caliper Life Sciences).
Statistical analysis
Gene expression analysis was performed using R
(http://www.r-project.org). Data from two experimen-
tal groups were compared with the t-test, chi-square
test or Fisher’s exact test, as appropriate. Survival
curves were drawn using the Kaplan-Meier method.
The differences of the Kaplan-Meier survival curves
were tested for statistical significance with the log
rank test, and the 95 % confidence intervals were cal-
culated. Multivariate analysis was done using the
COX proportional hazard model and a forward step-
wise method was used to bring variables into the
model. Further statistical analyses were done using
the SPSS 21.0 software (SPSS Inc.). A significant dif-
ference was declared if the p value from a two-tailed
test was less than 0.05.
Results
TIMP1 expression is significantly upregulated in human
colon cancer
We first browse Oncomine and found that the expression
level of TIMP1 was significantly high in tumor tissues
compared with the related normal mucosae [17–19]
(Fig. 1a-c). Furthermore, we analyzed data from The
Cancer Genome Atlas (TCGA) according to AJCC
stage. The expression data of TIMP1 genes from
these patients, obtained in RNA-Seq experiments
showed that the expression level of TIMP1 in colon
patients was augmented in stages I, II, III, and IV
compared with that in adjacent normal mucosa
(Fig. 1d). Western blot revealed that the protein levels
of TIMP1 were differentially upregulated in all 4
colon cancer samples compared to the matched adja-
cent non-tumor tissues (Fig. 2b).
Correlation between TIMP1 expression and the clinical
features of colon cancer
To determine whether TIMP1 is clinically correlated
with colon cancer progression, the expression of
TIMP1 was determined in a tissue microarray con-
taining 94 cases of primary colon tumors paired with
their normal colon mucosa tissue and 36 lymph node
metastases (LNM) specimens by immunohistochemis-
try. Among the 94 samples on the paired TMA, 57
(60.6 %) showed negative staining in normal mucosa.
In contrast, TIMP1 was prominently expressed in pri-
mary tumor specimens, with strong staining in 26
(27.7 %) samples, weak staining in 24 (25.5 %) sam-
ples, and negative staining in 44 (46.8 %) samples
(Table 1). Of the 36 samples of available lymph node
metastasis specimens, 29 samples (80.6 %) showed
TIMP1 overexpression (Table 1). Positive staining of
TIMP1 protein expression was observed mainly in the
cytoplasm of the cancer cells (Fig. 2a).
Summarization of the relationship between expres-
sion levels of TIMP1 and clinical parameters is shown
in Table 2. Our study revealed that upregulated
TIMP1 level was significantly correlated with the re-
gional lymph node metastasis (p = 0.033), distant me-
tastasis (p = 0.039), vascular invasion (p = 0.024) and
the AJCC stage (p = 0.026), while no association was
found between TIMP1 expression and age, gender, tumor
location, T-classification or differentiated degree.
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Fig. 1 Analysis of TIMP1 RNA expression on the basis of the Oncomine and Cancer Genome Atlas (TCGA) database. a-c Exhibition of TIMP1
expression of normal specimens and colorectal carcinoma from colorectal statistics in Oncomine dataset (a Graudens E, 2006; b Skrzypczak M,
2010; c, Hong Y, 2010). The expression fold changes were 2.169, 5.929 and 5.883 times, respectively, all p < 0.01. d TCGA dataset showed that the
TIMP1 level was increased in stages I, II, III, and IV compared with that in adjacent normal mucosa
Fig. 2 TIMP1 expression and pathologic features in colorectal cancer specimens. a Immunohistochemical staining of TIMP1. TIMP1 was localized
within the cytoplasm and overexpression in the tumor cells of colorectal cancer tissue. b Western blot analysis was performed to assess TIMP1
protein levels in 4 representative cases of colorectal cancer specimens. c The disease-free survival (DFS) and overall survival (OS) rates were estimated
by the Kaplan–Meier method. Both the DFS rate and OS rate of patients with TIMP1 positive primary tumor were significantly lower than
that of patients with TIMP1 negative primary tumor. d TIMP1 protein levels in colorectal cancer cell lines (scale bar = 40 μm)
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Overexpression of TIMP1 predicts poor clinical outcome
in human colon cancer
Kaplan-Meier survival analysis with the log-rank test for
disease-free survival (DFS) and overall survival (OS)
were undertaken to evaluate the relationship between
TIMP1 expression and patient prognosis (Fig. 2c). The
analysis revealed that patients with high levels of TIMP1
possessed shorter disease-free survival (DFS) time and
overall survival (OS) time than patients with low levels
of TIMP1 (p = 0.02 and p = 0.006, respectively).
Multivariate analysis was performed using the Cox
proportional hazards model for AJCC stage, TNM stage
and vascular invasion, and the expression of TIMP1 was
found to be an independent prognostic indicator to pre-
dict patient outcomes (Table 3). A significant association
was found between the high TIMP1 expression level
and lower 5-year DFS (HR =2.603, 95 % CI: 1.115–
6.077, p = 0.027) and OS survival (HR = 2.907, 95 %
CI: 1.254–6.737, p = 0.013). This suggests that TIMP1
is of clinical significance in the diagnosis and progno-
sis of patients with colon carcinomas.
Knockdown of TIMP1 inhibits the proliferation of colon
cancer cell
To further investigate the effects of TIMP1, shRNA was
used to knockdown TIMP1 in HCT116 and SW620
colon cell lines in which TIMP1 expression level was
higher than other cell lines (Fig. 2d). The efficacy of
TIMP1 knockdown was confirmed by real-time PCR
and western blot analysis (Fig. 3a, b). To evaluate the ef-
fects of TIMP1 knockdown (TIMP1-KD) on colon cell
proliferation, the expression of proliferation-related
genes (cyclinD1, p21 and p27) was detected by real-time
PCR and western blot analysis (Fig. 3a, b). The expres-
sion of cyclinD1 was downregulated, while P21 and P27
was upregulated in TIMP1-KD cells. Next, we per-
formed CCK-8 and plate colony formation assays to as-
sess the role of TIMP1 in colon cell growth which
showed that TIMP1-KD was associated with significantly
decreased cell proliferation and impaired colony forma-
tion ability compared with that of scramble cells (Fig. 3c,
d, p < 0.01). These results indicated that TIMP1 plays an
important role in colon cell proliferation.
Effects of suppression of TIMP1 in migration and invasion
In wound healing assays, less wound closure was ob-
served in TIMP1-KD colon cells when compared with
scramble group (Fig. 3e). These data further suggest that
TIMP1 plays an important role in cell migration. In
transwell cell invasion assays, representative data showed
that TIMP1-KD dramatically decreased the invasive ability
of colon cells (Fig. 3f), indicating that TIMP1 may have a
significant effect on cell migration and invasion. Further-
more, knockdown of TIMP1 significantly decreased
Table 1 Expression of TIMP1 protein in normal mucosa,
cancerous tissue, and LNM tissues
TIMP1 expression
Tissue sample n Negative Weak Positive P-value
Normal mucosa 94 57 (60.6 %) 22 (23.4 %) 15 (16.0 %) <0.01*
Cancerous tissue 94 44 (46.8 %) 24 (25.5 %) 26 (27.7 %)
LNM tissue 36 7 (19.4 %) 11 (30.6 %) 18 (50.0 %)
LNM lymph node metastasis
*p-value is based on chi-square test










< 65 43 (45.7 %) 21 (47.7 %) 22 (44.0 %) 0.717
≥ 65 51 (54.3 %) 23 (52.3 %) 28 (56.0 %)
Gender
Male 47 (50.0 %) 23 (52.3 %) 24 (48.0 %) 0.679
Female 47 (50.0 %) 21 (47.7 %) 26 (52.0 %)
Tumor location
Right 25 (26.6 %) 12 (27.3 %) 13 (26.0 %) 0.423
Transverse 9 (9.6 %) 5 (11.4 %) 4 (8.0 %)
Left 10 (10.6 %) 6 (13.6 %) 4 (8.0 %)
Others 50 (53.2 %) 21 (47.7 %) 29 (58.0 %)
T stage
T1 + T2 23 (24.5 %) 10 (22.7 %) 13 (26.0 %) 0.713
T3 + T4 71 (75.5 %) 34 (77.3 %) 37 (74.0 %)
N stage
N0 51 (54.3 %) 29 (65.9 %) 22 (44.0 %) 0.033*
N1 + N2 43 (45.7 %) 15 (34.1 %) 28 (56.0 %)
M stage
M0 80 (85.1 %) 41 (93.2 %) 39 (78.0 %) 0.039*
M1 14 (14.9 %) 3 (6.8 %) 11 (22.0 %)
Vascular invasion
No 85 (90.4 %) 43 (97.7 %) 42 (84.0 %) 0.024*
Yes 9 (9.6 %) 1 (2.3 %) 8 (16.0 %)
Differentiation
Well 27 (28.8 %) 9 (20.4 %) 18 (36.0 %) 0.186
Moderate 49 (52.1 %) 27 (61.4 %) 22 (44.0 %)
Poor 18 (19.1 %) 8 (18.2 %) 10 (20.0 %)
AJCC stage
I + II 42 (44.7 %) 25 (56.8 %) 17 (34.0 %) 0.026*
III + IV 52 (55.3 %) 19 (43.2 %) 33 (66.0 %)
*p < 0.05 indicates a significant association between the variables
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SLUG, one important EMT transfactor, which lead to as-
cending of E-cadherin, the epithelial marker, and decline
of Fibronectin, the mesenchymal marker (Fig. 4a, b).
Immunofluorescence staining also confirmed the knock
down effect of TIMP1 on the downregulation of Fibronec-
tin and upregulation of E-cadherin (Fig. 4c), suggesting
that TIMP1 may mediate epithelial–mesenchymal transi-
tion (EMT) initiation and colon progression.
TIMP1 plays an anti-apoptosis role in colon cells
To test whether expression of TIMP1 affects apoptosis
in colon cells, we performed an apoptosis assay by flow
cytometric analysis. TIMP1-KD resulted in a significant
increase in the percentage of apoptotic cells, compared
with the scramble group, in both HCT116 and SW620
(Fig. 5a, b) cells. Moreover, TIMP1-KD dramatically re-
duced the phosphoration of BCL2-Associated Agonist
Of Cell Death (BAD) (Fig. 5c), which play an important
role in apoptosis [20]. When BAD is phosphorylated,
it forms the BAD-(14-3-3) protein heterodimer. This
leaves Bcl-2 free to inhibit Bax-triggered apoptosis
[21, 22]. BAD phosphorylation is thus anti-apoptotic,
and BAD dephosphorylation is pro-apoptotic [22].
These results suggest that TIMP1 could increase anti-
apoptosis of colon cancer in BAD mediated phos-
phoration pathway.
Mechanisms of TIMP1 in colon cancer progression
To gain further insight into the biologic pathways in-
volved in colon cancer pathogenesis, GSEA analysis was
performed in TCGA datasets. Among all the predefined
‘oncogenic signature’ gene sets, the EMT pathway was
identified with the strongest association with TIMP1
expression (Additional file 2: Figure S2). The other top-
scoring hallmarks included angiogenesis, apoptosis,
KRAS, hypoxia and so on. Several of these hallmarks are
related to PI3K and MAPK signaling pathways, activa-
tion of which are frequently aberrantly activated in
human cancers and contributes to enhance cell prolifer-
ation and survival. As shown in Fig. 5c and d, transfec-
tion with TIMP1-KD significantly decreased FAK, AKT,
ERK1/2 and JNK phosphorylation in both HCT116 and
SW620 cells; however, no detectable changes in the
total levels of FAK, AKT, ERK1/2 and JNK were ob-
served (Fig. 5d). Thus, the data suggested that the
FAK-PI3K/AKT and MAPK pathway might participate
in TIMP1-induced cell proliferation, metastasis and
anti-apoptosis in colon cells. To illustrate its co-
worked genes, PPIs network was built from the
STRING resource (Additional file 1: Figure S1). Result
shows that TIMP1, was highly correlated with several
stars molecules, such as MMPs, EGFR, JUN, TGF-β
and SMADs, etc. This hints that TIMP1 would be a
crucial marker which is valuable for further research.
The functional impact of TIMP1 knockdown in colon cell
invasion in vivo
We further tested whether knockdown of TIMP1 could
suppress the tumorigenicity of colon cells in vivo using a
xenograft model in the nude mice. As shown in Fig. 6a,
the tumors injected with TIMP1-KD were significantly
smaller than the tumors treated with scramble cells.
Tumor growth and tumor weight was significantly inhib-
ited in TIMP1-KD injected tumors (Fig. 6b, c, p < 0.01),
indicating that TIMP1 exert an oncogenic role during
colon progression. We then explored the functional im-
pact of TIMP1 on metastasis in vivo using a nude mouse
metastatic tumor models. Different stable cells were
transplanted into BALB/c-nu/nu mice via tail vein injec-
tion. We found that less subcutaneous metastasis were
detected after injection of TIMP1-KD cells when com-
pared with the injection of scramble cells (Fig. 6d-f ).
These data suggest that TIMP1 expression plays a crit-
ical role in colon cell motility and metastasis.
Discussion
TIMP1, which is a kind of soluble protein release by
endometrial cells, fibroblasts and cancer cells, has been
demonstrated to be associated with poor prognosis for a
variety of cancers [12, 23, 24]. To find the involvement
of TIMP1 in colon cancer, public data, such as Onco-
mine and TCGA, was used to evaluate the expression of
this gene in colon patients, and data from 94 patients
with primary colon cancer also present with elevated
Table 3 Multivariate Cox proportional hazards analysis for disease-free survival (DFS) and overall survival (OS)
Variable Multivariate analysis (DFS) Multivariate analysis (OS)
P-value HR (95%CI) P-value HR (95%CI)
AJCC stage (I/II vs. III/IV) 0.037* 2.621 (1.011–6.668) 0.029* 2.915 (1.113–7.634)
N stage (N0 vs. N1 + N2) 0.043* 2.354 (1.027–5.395) 0.033* 2.785 (1.086–7.141)
M stage (M0 vs. M1) 0.049* 3.649 (1.008–13.214) 0.035* 2.465 (1.067–5.696)
Vascular invasion (Yes vs. No) 0.038* 2.488 (1.051–5.891) 0.024* 2.945 (1.151–7.535)
TIMP1 expression (Negative vs. Positive) 0.027* 2.603 (1.115–6.077) 0.013* 2.907 (1.254–6.737)
AJCC American Joint Committee on Cancer, HR hazard ratio, CI confidence interval
*p < 0.05 indicates a significant association between the variables
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levels of TIMP1 which has the potential to predict the
survival rate of patients. In this study, analysis of TIMP1
expression level and patients’ clinical outcomes sug-
gested that those with high TIMP1 expression had
poorer survival than those with low TIMP1 expression.
Remarkably, TIMP1 is a secretory protein that could be
detected in blood and body fluid, thus making it a good
potential tumor marker. However, the significance of
TIMP1 and its mechanism of action in the progression
of colon cancer have been rarely reported.
Despite some researches have proved that TIMP-1 has
a major role as inhibitor of MMPs [25], its role in tumor
Fig. 3 Functional roles of TIMP1 in vitro. a QPCR showed that TIMP1 was knocked down in HCT116 and SW620 cells; cyclinD1 was decreased
while p21 and p27 was upregulated in TIMP1-KD cells. b western blot confirmed that TIMP1, CyclinD1 was decreased while P21 and P27 was
upregulated in TIMP1-KD cells. c TIMP1-KD inhibited CRC cell growth in vitro. d TIMP1-KD inhibited CRC cell colony formation in vitro. e Cell would
healling ability was impaired in TIMP1-KD cells (200×). f Chamber invision ability was damaged in TIMP1-KD cells (200×) (scale bar = 20 μm)
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invasion and metastasis appears to be more complex. It
has been believed that TIMP-1 has a dual function, one
of which is based on MMPs dependent anti-proteolytic
activity with the other MMP-independent cell growth
activity [26]. In the present study, our experiments
showed that depletion of TIMP1 could suppress colon
cancer cell proliferation, migration and invasion in vitro,
and suppress the tumorigenicity and metastasis of colon
cells in vivo. In addition, TIMP1 could also increase
anti-apoptosis of colon cancer in BAD mediated phos-
phoration pathway. These results suggest that TIMP1
plays an important role in proliferation, invasion and
metastasis of colon cancer and that TIMP1 may be a
crucial therapeutic target.
To find the involved mechanism of TIMP1 in colon
cancer, public data, such as TCGA, and high throughput
analysis, such as STRING and GSEA was used to locate
the pathway and correlated molecules which are related to
TIMP1. These bioinformatics significantly pointed the
function of TIMP1 to EMT, apoptosis and several other
crucial pathways. To validate these predictions, biological
experiment was conducted. We showed that TIMP1 over-
expression is associated with constitutive activation of
FAK, a signaling molecule known to be critical to the cell
survival pathway [27]. FAK was shown to be the upstream
regulator of the PI3K-AKT pathway [28, 29]. Phosphoryl-
ation of AKT could upregulate cyclin D1 and downregu-
late the cyclin D kinase (CDK) inhibitors p21 and p27,
Fig. 4 TIMP1 promotes CRC metastasis through EMT. a QPCR showed that E-cadherin was upregulated while SLUG and Fibronectin was
downregulated in TIMP1-KD cells. b Western blot confirmed that E-cadherin was upregulated while SLUG and Fibronectin was downregulated in
TIMP1-KD cells. c Immunofluorescence showed that E-cadherin was upregulated while Fibronectin was downregulated in TIMP1-KD cells d The relative
expression of E-cadherin and Fibronectin in Scramble and TIMP1-KD cells (scale bar = 25 μm)
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which promotes cell cycle progression. Besides, AKT
phosphorylates BAD, which no longer interacts with Bcl-2
(anti-apoptotic members of the bcl-2 family), resulting
in Bcl-2 activation. Similarly, MAPK family can also
phosphorylate BAD protein, resulting in release of anti-
apoptotic Bcl-2 in the cells (Additional file 3: Figure S3).
Although TIMP1 could inhibit MMP facilitated break-
down of the ECM and was thought to be metastasis
inhibitor [30], we found that TIMP1 could promote
colon cancer invasion and metastasis by development
of EMT transcription factors such as SLUG, leading
to downregulation of epithelial marker E-cadherin and
upregulation of mesenchymal marker fibronectins. In
conclusion, by analyzing data from public and our own,
we clearly illustrated that TIMP1 actually plays a great
role in cancer progression, which is independent of MMP,
and the FAK - PI3K/AKT and MAPK pathway might play
an important role in TIMP1-induced cell proliferation,
metastasis and anti-apoptosis. Besides, the paradoxical
report of TIMP1 as an inhibitor of MMPs and poor
Fig. 5 Effects of TIMP1 on apoptosis and its related pathway. a-b TIMP1-KD significantly increased the apoptosis rate of CRC cells; c Levels of
pFAK/FAK, pBAD/BAD were detected in Scramble and TIMP1-KD cells. d Western blot of pAKT/AKT, pERK/ERK, pJNK/JNK in Scramble and
TIMP1-KD cells
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prognosis marker of colon cancer as well, could be
explained by its MMP independent function, which
suggests the elevation of TIMP1 in colon cancer is
not a feedback regulation of the upregulation of
MMP, but is a vitally important and self-governed
effect in colon cancer. All these results provided a
new method to make prognosis prediction and
suggested that TIMP1 could be a therapeutic marker.
Conclusions
In summary, the present study identified that TIMP1
is overexpressed in colon tumor samples and that
dysregulated TIMP1 expression, which occurs fre-
quently in colon cancer, leads to tumor proliferation,
metastasis and anti-apoptosis by FAK-PI3K/AKT and
MAPK pathway. In animal experiments, the in vivo
tumorigenicity and metastasis were weakened effect-
ively by downregulation of TIMP1. These results sug-
gest that TIMP1 signaling is a promising new
molecular target for novel preventive and therapeutic
strategies for this malignancy, and TIMP1 expression
is critical for the progression and invasiveness of
colon cancer. However, further explorations are
needed to fully elucidate the molecular mechanisms
governing TIMP1 gene dysregulation and its role in
colon cancer progression.
Additional files
Additional file 1: Figure S1. PPIs network from the STRING resource.
TIMP1 was highly correlated with stars molecules, such as MMPs, EGFR,
JUN, TGF-β and SMADs, etc. (TIF 3877 kb)
Additional file 2: Figure S2. Inferring the functions of TIMP1 by
Gene Set Enrichment Analysis (GSEA) in TCGA CRC dataset.
Enrichment plots are shown for a set of activated genes of EMT,
Apical junction, Apoptosis, IL2-STAT5, KRAS, Hypoxia, Angiogenesis,
Hedgehog and TGF-βpathway. The enrichment score (ES, green line)
represents the degree to which the gene set is over-represented at
the top or bottom of the ranked list of genes. Black bars mean the
position of genes belonging to the gene set in the ranked list of
genes included in the analysis. (TIF 4894 kb)
Additional file 3: Figure S3. Schematic representation for the TIMP1
regulatory pathway proposed in this study. TIMP1 activates FAK/PI3K-
AKT and MAPK pathway, which facilitated AKT/ERK phosphorylation.
This promotes the activation of BAD, cyclin D1, P21, P27 and other
Transcription substrates, leading to potentiation of cell antiapoptosis,
proliferation and invasion in CRC. (TIF 903 kb)
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